Q4 2017 Bioverativ Inc Earnings Call

14/2/2018 5:00

Conference Call Bioverativ Inc

Bioverativ Inc Conference call will be held on Feb 14, 2018. During the earnings conference call's session Bioverativ Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Bioverativ Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
Bioverativ is a global biotechnology company focused on the discovery, research, development and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. We market two products, ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor, thereby making the product last longer in a person's blood than traditional factor therapies.    
Read more Conference Call

Bioverativ Inc (BIVV)

225 Binney Street, Cambridge Massachusetts 02142, United States